Literature DB >> 11783215

[Serapharmacological effect of fuzheng huayu 319 Decoction on expression of type I collagen and transforming growth factor beta 1 in hepatic stellate cells].

C Liu1, X Wang, P Liu.   

Abstract

OBJECTIVE: To investigate the main serapharmacological mechanism of antifibrotic action of Fuzheng Huayu 319 Decoction (FHD) at cellular and molecular level.
METHODS: Hepatic stellate cells (HSC) were isolated from the normal rats and subcultured. Normal rats were medicated with FHD and their blood serum collected to prepare the medicated serum, which was incubated with the subcultured HSC. Then, the extra- and intracellular collagen synthetic rates were assayed with collagenase digestion method, type I collagen content in the medium measured with ELISA, transforming growth factor beta 1 (TGF beta 1) protein production semiquantified by immunocytochemistry stain and image analysis system, the gene expressions of type I procollagen and TGF beta 1 analyzed by RT-PCR.
RESULTS: FHD medicated serum could obviously inhibit the extra- and intracellular collagen synthetic rates, decreased type I procollagen mRNA expression and its secretion, downregulate TGF beta 1 mRNA and its protein expression.
CONCLUSION: FHD could inhibit HSC activation markedly, the main mechanism of its antifibrotic action may be the medicated serum inhibition on type I procollagen and TGF beta 1 gene expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11783215

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  9 in total

Review 1.  Fuzheng huayu capsule in the treatment of liver fibrosis: clinical evidence and mechanism of action.

Authors:  Ping Liu
Journal:  Chin J Integr Med       Date:  2012-03-21       Impact factor: 1.978

2.  Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Lie-Ming Xu; Cheng-Hai Liu; Ke-Wei Sun; De-Chang Hu; You-Kuan Yin; Xia-Qiu Zhou; Mo-Bin Wan; Xiong Cai; Zhi-Qing Zhang; Jun Ye; Ren-Xing Zhou; Jia He; Bao-Zhang Tang
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

3.  Effects of different ingredients of zedoary on gene expression of HSC-T6 cells.

Authors:  Yuan Jiang; Ze-Song Li; Fu-Sheng Jiang; Xin Deng; Cong-Shun Yao; Guang Nie
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

4.  The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach.

Authors:  Xing Lv; Huijun Wang; Ruoming Wu; Xiaoyan Shen; Guan Ye
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-25       Impact factor: 2.629

5.  Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice.

Authors:  Yan-Hong Jia; Rong-Qi Wang; Hong-Mei Mi; Ling-Bo Kong; Wei-Guang Ren; Wen-Cong Li; Su-Xian Zhao; Yu-Guo Zhang; Wen-Juan Wu; Yue-Min Nan; Jun Yu
Journal:  Lipids Health Dis       Date:  2012-03-28       Impact factor: 3.876

6.  Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis.

Authors:  Yan-yan Tao; Xiu-chuan Yan; Tao Zhou; Li Shen; Zu-long Liu; Cheng-hai Liu
Journal:  BMC Complement Altern Med       Date:  2014-11-18       Impact factor: 3.659

7.  The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability - A Network Pharmacology and Transcriptomics Approach.

Authors:  Xinrui Xing; Si Chen; Ling Li; Yan Cao; Langdong Chen; Xiaobo Wang; Zhenyu Zhu
Journal:  Front Pharmacol       Date:  2018-05-24       Impact factor: 5.810

8.  Effect of Fuzheng Huayu formula and its actions against liver fibrosis.

Authors:  Chenghai Liu; Yiyang Hu; Lieming Xu; Cheng Liu; Ping Liu
Journal:  Chin Med       Date:  2009-06-29       Impact factor: 5.455

9.  A randomized controlled study of fuzheng huayu capsule for prevention of esophageal variceal bleeding in patients with liver cirrhosis.

Authors:  Jie Gu; Qin Zhang; Dongying Xue; Hong Cai; Lieming Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-21       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.